Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | -6.78% |
|
-25.34% | -48.11% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.11% | 14.37M | |
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Earnings Flash (LUMO) LUMOS PHARMA Posts Q2 Revenue $527,000, vs. Street Est of $0.2M